Misoprostol for women's health: A review

被引:65
作者
Blanchard, K
Clark, S
Winikoff, B
Gaines, G
Kabani, G
Shannon, C
机构
[1] Populat Council, New York, NY 10017 USA
[2] Populat Council, Johannesburg, South Africa
关键词
D O I
10.1016/S0029-7844(01)01701-X
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To review published literature on misoprostol for women's health indications to provide a synthesis of available information and highlight areas in need of additional research. DATA SOURCES: Studies were identified through searches of medical literature databases including MEDLINE, Cochrane Database, and Popline, in addition to a review of references from identified articles. STUDY SELECTION: We included all studies reported in English and published before March 31, 2001, which evaluated the efficacy of misoprostol alone for labor and delivery, evacuation of the uterus after pregnancy failure and induced abortion. Studies were not excluded based on quality or sample size. TABULATION, INTEGRATION, AND RESULTS: Misoprostol shows promise for all of the women's health indications addressed. Currently available data, though, are often hard to interpret because of variations in regimen, dose, and outcome measures. The low cost, case of administration and storage, and widespread availability of misoprostol make it particularly appealing for developing countries. Because many of the women's health problems for which misoprostol could be prescribed currently cause significant mortality and morbidity, increased access to and information on use of misoprostol could help improve women's health especially where these problems are most severe. CONCLUSION: Further research is needed to identify optimal regimens for misoprostol for obstetric and gynecologic health indications. Registering misoprostol with national drug regulatory authorities for any of several women's health indications could help increase access to and safe use of this drug. Provider training would be a logical subsequent step. (C) 2002 by the American College of Obstetricians and Gynecologists.
引用
收藏
页码:316 / 332
页数:17
相关论文
共 133 条
[71]   Comparison of labor induction with misoprostol vs oxytocin/prostaglandin E(2) in term pregnancy [J].
Kadanali, S ;
Kucukozkan, T ;
Zor, N ;
Kumtepe, Y .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1996, 55 (02) :99-104
[72]   Misoprostol is more efficacious for labor induction than prostaglandin E2, but is it associated with more risk? [J].
Kolderup, L ;
McLean, L ;
Grullon, K ;
Safford, K ;
Kilpatrick, SJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (06) :1543-1548
[73]   A randomized trial of misoprostol and oxytocin for induction of labor: Safety and efficacy [J].
Kramer, RL ;
Gilson, GJ ;
Morrison, DS ;
Martin, D ;
Gonzales, JL ;
Qualls, CR .
OBSTETRICS AND GYNECOLOGY, 1997, 89 (03) :387-391
[74]   A randomised comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy [J].
Lawrie, A ;
Penney, G ;
Templeton, A .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 (11) :1117-1119
[75]  
Lee H. Y., 1997, SMJ, V38, P292
[76]   Intracervical misoprostol as an effective method of labor induction at term [J].
Liu, HS ;
Chu, TY ;
Chang, YK ;
Yu, MH ;
Chen, WH .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1999, 64 (01) :49-53
[77]   Misoprostol dose-related shivering and pyrexia in the third stage of labour [J].
Lumbiganon, P ;
Hofmeyer, J ;
Gülmezoglu, AM ;
Pinol, A ;
Villar, J .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (04) :304-308
[78]   A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion [J].
MacIsaac, L ;
Grossman, D ;
Balistreri, E ;
Darney, P .
OBSTETRICS AND GYNECOLOGY, 1999, 93 (05) :766-770
[79]  
MAGITIBAY PM, 1998, J MATERN FETAL MED, V17, P15
[80]  
Merrell DA, 1995, S AFR MED J, V85, P1088